Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Refractory Crow-Fukase Syndrome (POEMS Syndrome) Successfully Treated with High-Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation

  • 45 Accesses

  • 2 Citations

Abstract

Crow-Fukase syndrome (CFS) is a multisystemic disorder. Because it is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, sclerotic bone lesions, and skin changes it is also known as POEMS syndrome. Extravascular volume overload is also one of the main symptoms. Uncontrollable extravascular volume overload is one of the major causes of death and one of the negative prognostic factors. Control of the extravascular volume overload is an important therapeutic strategy for this syndrome. We report here a case of CFS with extravascular volume overload resulting in pleural effusion and massive edema in the lower extremities, which was refractory to oral administration of melphalan and prednisolone. The patient's condition correlated with the serum level of vascular endothelial growth factor and markedly improved after administration of high-dose melphalan (200 mg/m2) followed by autologous peripheral blood stem cell transplantation. This approach should be considered in patients with CFS who fail to respond to conventional chemotherapy and have uncontrollable extravascular volume overload.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Crow RS Peripheral neuritis in myelomatosis.Br Med J. 1956;2:802–804.

  2. 2.

    Shimpo S, Nishitani H, Tsunematsu T, et al. Solitary plasmacytoma with polyneuritis and endocrine disturbances [in Japanese].Nippon Rinsho. 1968;26:2444–2456.

  3. 3.

    Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature.Medicine. 1980;59:311–322.

  4. 4.

    Nakanishi T, Sobue I, Tokuyama Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan.Neurology. 1984;34:712–720.

  5. 5.

    Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome.N Engl J Med. 1992;327:1919–1923.

  6. 6.

    Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome.Blood. 2003;101:2496–2506.

  7. 7.

    Benito-Leon J, Lopez-Rios F, Rodriguez-Martin FJ, Madero S, Ruiz J. Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responsive to intravenous immunoglobulin and radiotherapy.J Neurol Sci. 1998;158:113–117.

  8. 8.

    Huang CC, Chu CC. Poor response to intravenous immunoglobulin therapy in patients with Castleman's disease and the POEMS syndrome.J Neurol. 1996;243:726–727.

  9. 9.

    Silberstein LE, Duggan D, Berkman EM. Therapeutic trial of plasma exchange in osteosclerotic myeloma associated with the POEMS syndrome.J Clin Apheresis. 1985;2:253–257.

  10. 10.

    Kuwabara S, Hattori T, Shimoe Y, Kamitsukasa I. Long term melphalan-prednisolone chemotherapy for POEMS syndrome.J Neurol Neurosurg Psychiatry. 1997;63:385–387.

  11. 11.

    Rotta FT, Gradley WG. Marked improvement of severe polyneuropathy associated with multifocal osteosclerotic myeloma following surgery, radiation, and chemotherapy.Muscle Nerve. 1997;20:1035–1037.

  12. 12.

    Hogan WJ, Lacy MQ, Wiseman GA, Fealey RD, Dispenzieri A, Gertz MA. Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation.Bone Marrow Transplant. 2001;28:305–309.

  13. 13.

    Rovira M, Carreras E, Blade J, et al. Dramatic improvement of POEMS syndrome following autologous haematopoietic cell transplantation.Br J Haematol. 2001;115:373–375.

  14. 14.

    Peggs KS, Paneesha S, Kottaridis PD, et al. Peripheral blood stem cell transplantation for POEMS syndrome.Bone Marrow Transplant. 2002;30:401–404.

  15. 15.

    Jaccard A, Royer B, Bordessoule D, Brouet JC, Fermand JP. High- dose therapy and autologous blood stem cell transplantation in POEMS syndrome.Blood. 2002;99:3057–3059.

  16. 16.

    Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome.Lancet. 1996;347:702.

  17. 17.

    Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome.Muscle Nerve. 1998;21:1390–1397.

  18. 18.

    Gherardi RK, Belec L, Soubrier M, Malapert D, Zuber M, Viard JP. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome.Blood. 1996;87:1458–1465.

  19. 19.

    Koga H, Tokunaga Y, Hisamoto T, et al. Ratio of serum vascular endothelial growth factor to platelet count correlates with disease activity in a patient with POEMS syndrome.Eur J Intern Med. 2002;13:70–74.

  20. 20.

    Sobue G, Doyu M, Watanabe M, Hayashi F, Mitsuma T. Extensive demyelinating changes in the peripheral nerves of Crow-Fukase syndrome: a pathological study of one autopsied case.Acta Neuropathol. 1992;84:171–177.

  21. 21.

    Saida K, Kawakami H, Ohta M, Iwamura K. Coagulation and vascular abnormalities in Crow-Fukase syndrome.Muscle Nerve. 1997;20:486–492.

  22. 22.

    Gherardi R, Baudrimont M, Kujas M, et al. Pathological findings in three non-Japanese patients with the POEMS syndrome.Virchows Arch A Pathol Anat Histopathol. 1988;413:357–365

  23. 23.

    Baumgartner I, Rauh G, Pieczek A, et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor.Ann Inter Med. 2000;132:880–884.

  24. 24.

    Attal M, Harousseau JJ, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.N Engl J Med. 1996;335:91–97.

Download references

Author information

Correspondence to Jun Ozaki or Hirokazu Okumura or Kouji Iwamoto or Shigeru Shimadoi or Shinichi Yamanaka or Shigeki Ohtake or Shinji Nakao.

About this article

Cite this article

Ozaki, J., Okumura, H., Iwamoto, K. et al. Refractory Crow-Fukase Syndrome (POEMS Syndrome) Successfully Treated with High-Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation. Int J Hematol 79, 95–99 (2004). https://doi.org/10.1007/BF02983541

Download citation

Key words

  • Crow-Fukase syndrome
  • Autologous peripheral blood stem cell transplantation
  • Extravascular volume overload
  • High-dose melphalan